chr14-102933764-T-TG
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PVS1_ModeratePM2
The NM_006035.4(CDC42BPB):c.5083_5084insC(p.His1695ProfsTer16) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000149 in 1,346,356 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: not found (cov: 33)
Exomes 𝑓: 0.0000015 ( 0 hom. )
Consequence
CDC42BPB
NM_006035.4 frameshift
NM_006035.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 9.53
Genes affected
CDC42BPB (HGNC:1738): (CDC42 binding protein kinase beta) This gene encodes a member of the serine/threonine protein kinase family. The encoded protein contains a Cdc42/Rac-binding p21 binding domain resembling that of PAK kinase. The kinase domain of this protein is most closely related to that of myotonic dystrophy kinase-related ROK. Studies of the similar gene in rat suggested that this kinase may act as a downstream effector of Cdc42 in cytoskeletal reorganization. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 4 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.0103 CDS is truncated, and there are 0 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CDC42BPB | NM_006035.4 | c.5083_5084insC | p.His1695ProfsTer16 | frameshift_variant | 37/37 | ENST00000361246.7 | |
CDC42BPB | NM_001411054.1 | c.5005_5006insC | p.His1669ProfsTer16 | frameshift_variant | 36/36 | ||
CDC42BPB | XM_005268227.2 | c.5134_5135insC | p.His1712ProfsTer16 | frameshift_variant | 38/38 | ||
CDC42BPB | XM_005268228.2 | c.5056_5057insC | p.His1686ProfsTer16 | frameshift_variant | 37/37 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CDC42BPB | ENST00000361246.7 | c.5083_5084insC | p.His1695ProfsTer16 | frameshift_variant | 37/37 | 1 | NM_006035.4 | P1 | |
ENST00000560931.1 | n.197dup | non_coding_transcript_exon_variant | 1/2 | 3 | |||||
CDC42BPB | ENST00000559043.2 | c.5005_5006insC | p.His1669ProfsTer16 | frameshift_variant | 36/36 | 5 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome AF: 0.00000149 AC: 2AN: 1346356Hom.: 0 Cov.: 30 AF XY: 0.00000300 AC XY: 2AN XY: 665720
GnomAD4 exome
AF:
AC:
2
AN:
1346356
Hom.:
Cov.:
30
AF XY:
AC XY:
2
AN XY:
665720
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 08, 2022 | Variant summary: CDC42BPB c.5083dupC (p.His1695ProfsX16) results in a premature termination codon in the last exon of the protein, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay. Truncations downstream of this position have not been reported in HGMD or ClinVar. The variant allele was found at a frequency of 1.6e-05 in 127116 control chromosomes. To our knowledge, no occurrence of c.5083dupC in individuals affected with Chilton-Okur Neurodevelopmental Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as VUS. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at